Tesofensine

What Is Tesofensine?

Tesofensine is a synthetic compound originally developed for Parkinson's and Alzheimer's disease research before its appetite-suppressing effects redirected interest toward obesity. Unlike GLP-1-based medications, it does not work through gut hormone receptors; it blocks reuptake of serotonin, norepinephrine, and dopamine in the brain.

A Phase II trial published in The Lancet in 2008 reported weight loss roughly double what was seen with obesity drugs approved at the time. The Lancet later issued an expression of concern about the trial's data in 2013, and a separate cardiovascular safety signal has blocked regulatory progress.

What Tesofensine Is Being Researched For

• Weight Loss in Obesity

  The Phase II trial found approximately 10% placebo-subtracted weight loss over 24 weeks with tesofensine 0.5 mg.^[1]

• Energy Metabolism and Appetite in Humans

  A separate controlled study in overweight and moderately obese men found effects on 24-hour energy expenditure and fat oxidation alongside appetite suppression.^[2]

• Mechanistic Basis for Appetite Effects

  Preclinical research in obese rats linked the hypophagic effect to indirect stimulation of alpha-1 adrenergic and dopamine D1 receptor pathways.^[3]

How Tesofensine Works

• Blocking Three Neurotransmitter Reuptake Systems

  Research points to tesofensine inhibiting reuptake of serotonin, norepinephrine, and dopamine, keeping more of each neurotransmitter active in brain synapses. In vitro potency was strongest at the norepinephrine transporter, followed by dopamine and serotonin.^[3]

• Suppressing Appetite Through Specific Receptor Pathways

  Research points to appetite suppression being mediated indirectly through alpha-1 adrenergic and dopamine D1 receptor activation downstream of the reuptake-blocking action.^[3]

• An Unresolved Safety and Data Integrity Question

  The strongest efficacy data comes from a trial with an unresolved expression of concern from The Lancet, while separate cardiovascular safety findings prevented regulatory advancement. Both facts are essential context.

Reconstitution and Handling

Tesofensine is typically supplied in capsule form for oral research use. Capsules should be stored in a cool, dry place away from direct light and handled according to the specific product's labeling since formulations can vary by supplier.

Key Takeaways

Tesofensine's headline efficacy data comes with two serious complications: an unresolved 2013 expression of concern from The Lancet about the cited trial's data and a separate cardiovascular safety signal that stalled regulatory progress. Its triple monoamine mechanism is distinct from GLP-1 approaches, but the strength of its evidence is more contested than the headline weight-loss figure suggests.

Frequently Asked Questions

Sources and Research

1. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906-1913.
2. Sjödin A, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes (Lond). 2010;34(11):1634-1643.
3. Axel AM, Mikkelsen JD, Hansen HH. Tesofensine, a Novel Triple Monoamine Reuptake Inhibitor, Induces Appetite Suppression by Indirect Stimulation of α1 Adrenoceptor and Dopamine D1 Receptor Pathways in the Diet-Induced Obese Rat. Neuropsychopharmacology. 2010;35(7):1464-1476.